COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)

Kubas, Aleksandra; Małecka-Wojciesko, Ewa

doi:10.3390/jcm11092676

Cited by 13 publications

(8 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mass vaccination programs provide the best opportunity for controlling transmission and protecting populations [60], but this is a difficult decision for IBD patients as no confirmed data are presently available regarding COVID-19 vaccines in this population due to their exclusion from the conducted clinical trials [61]. The good news is that some recent studies have provided some clinical evidence [62][63][64]. Drug use after COVID-19 infection has also become a psychological burden for Crohn's disease patients.…”

Section: Discussionmentioning

confidence: 99%

Patients’ perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media

Sun

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

Aim The aim of this study was to explore the experience and perceptions of patients with Crohn’s disease in China. Methods Data mining was used to investigate posts in Crohn’s disease online medical communities. The data were collected through the crawler code, and latent Dirichlet allocation (LDA) and grounded theory were used to mine the theme features after data cleaning. Results In analyzing the topic characteristics of online posts, LDA divided 6757 posts into 15 topics on four aspects: seeking disease information, making decisions on medication use, psychological burden, and communicating about diet and nutrition. Conclusion Overall, social media is patient-centric and helps us better understand the experiences and perceptions of patients. This study can help medical staff predict the thoughts and concerns of Crohn's disease patients during the treatment process, facilitate doctor-patient communication, and assist in the formulation of medical policies.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients’ perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media

Sun

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Data on patients with inflammatory bowel disease (IBD) treated with high doses of systemic corticosteroids, infliximab, or infliximab and immunomodulators showed that they present a blunted response to the anti-SARS-CoV-2 vaccination [ 133 ]. However, a study on humoral and spike-specific T cell responses in patients with IBD who were on antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors, and/or other biologic treatment (anti-integrin or anti-p40) for up to 6 months after completing two-dose COVID-19 mRNA vaccination showed that a spike-specific T cell response was not only induced in treated patients with IBD at levels similar to those of healthy individuals, but also was sustained at a higher magnitude for up to 6 months after vaccination, particularly in those treated with TNF inhibitor therapy [ 134 ].…”

Section: Immune Response To Sars-cov-2 Vaccinationmentioning

confidence: 99%

Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences

et al. 2022

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a robust immune response. The development of systemic inflammation leads to a hyperinflammatory state due to cytokine release syndrome during severe COVID-19. The emergence of many new SARS-CoV-2 variants across the world deteriorates the protective antiviral immunity induced after infection or vaccination. The innate immune response to SARS-CoV-2 is crucial for determining the fate of COVID-19 symptomatology. T cell-mediated immunity is the main factor of the antiviral immune response; moreover, SARS-CoV-2 infection initiates a rapid B-cell response. In this paper, we present the current state of knowledge on immunity after COVID-19 infection and vaccination. We discuss the mechanisms of immune response to various types of vaccines (nucleoside-modified, adenovirus-vectored, inactivated virus vaccines and recombinant protein adjuvanted formulations). This includes specific aspects of vaccination in selected patient populations with altered immune activity (the elderly, children, pregnant women, solid organ transplant recipients, patients with systemic rheumatic diseases or malignancies). We also present diagnostic and research tools available to study the anti-SARS-CoV-2 cellular and humoral immune responses.

show abstract

“…To identify patients likely to develop severe COVID-19 and to facilitate medical decision-making, a multivariate model of predicting adverse outcomes was developed and validated [ 12 ]. The reality changed with the introduction of vaccines, which play a key role in the fight against the pandemic, but IBD patients have not been included in studies [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study

Karłowicz¹,

Lewandowski²,

Tulewicz-Marti³

et al. 2024

View full text Add to dashboard Cite

Introduction Inflammatory bowel disease (IBD) patients use a wide variety of immunosuppressive drugs, including biologics, but their effect on SARS-CoV-2 vaccine antibody levels remains a mystery. Aim We analysed whether the drugs used in the treatment of IBD patients could affect the concentration of SARS-CoV-2 antibodies. Material and methods This is a prospective, single-centre evaluation of the persistence of SARS-CoV-2 antibodies after vaccination at various time points: every 2 months throughout the 6 th month after the first dose. Results We included a total of 346 vaccinated IBD patients in the study. A negative correlation between antibody level and time from full vaccination was confirmed for the following types of therapy: infliximab (rho = –0.32, p < 0.001), adalimumab (rho = –0.35, p = 0.025), and vedolizumab (rho = –0.50, p < 0.001). In the case of other, long-term drug administration, a negative correlation between antibody level and time from full vaccination was confirmed for mesalazine (rho = –0.35, p < 0.001), budesonide (rho = –0.58, p = 0.004), systemic glucocorticoids (rho = –0.58, p < 0.001), and azathioprine (rho = –0.44, p < 0.001). Conclusions Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.

show abstract

COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)

Cited by 13 publications

References 58 publications

Patients’ perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media

Patients’ perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media

Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences

SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study

Contact Info

Product

Resources

About